MTOR and neoplasm: Indeed, targeting both SK isoforms may be the best strategy to overcome tissue and cell type-specific differences in the roles of the SKs in different cancers, and in agreement, dual SK1/SK2 inhibitors show significant decreases in tumor burden in vivo [36, 37].